Most BPC-157 write-ups argue about whether it heals tendons. Almost none deal with a plainer question: where does the peptide actually go once it's in the body, and for how long? That question has an answer — and it's the most awkward number in the whole BPC-157 research file. In rats given BPC-157 intravenously, the average elimination half-life was about 15 minutes. In beagle dogs it was closer to five. Meanwhile the effects attributed to it are described in days. This post looks at that gap, what a 2026 pharmaceutics review says is still missing before anyone can call this a drug candidate, and where the compound sits legally if you're asking is BPC-157 legal in Australia.

What is BPC-157, in one paragraph

BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a fragment of a protein found in human gastric juice. It's been studied since the early 1990s, mostly in rodents, for wound healing, gut protection, tendon and ligament repair and a long list of other organ systems. It is not approved as a medicine in any country. Our compound overview sits at /peptides/bpc-157, alongside the rest of the peptides library.

The pharmacokinetics nobody quotes

The most useful pharmacokinetic dataset on BPC-157 isn't from the Croatian lab that discovered it. It's a 2022 paper in Frontiers in Pharmacology by He and colleagues, who ran a full ADME package — absorption, distribution, metabolism, excretion — in rats and beagle dogs using tritium-labelled peptide.

The headline numbers:

  • Elimination half-life under 30 minutes in both species, with reported figures around 15 minutes in rats and roughly five minutes in dogs after intravenous dosing.
  • Peak plasma levels within about nine minutes of intramuscular injection.
  • Absolute bioavailability after intramuscular injection of roughly 14–19% in rats and 45–51% in dogs — a fourfold species difference in the same experiment, which is itself a warning about extrapolating to humans.
  • Excretion via urine and bile, with the peptide rapidly chopped into smaller fragments and then into free amino acids that re-enter ordinary amino acid metabolism. Six metabolites were identified.

That last point matters. BPC-157 doesn't linger. It is dismantled into parts that are indistinguishable from the protein in your lunch.

Why the half-life is a problem, not a footnote

A short half-life isn't disqualifying on its own — plenty of approved drugs clear fast and still work, because they trigger a durable downstream change. But the case for BPC-157 rests on exactly that assumption, and the assumption has never been tested properly. A 2026 review in Pharmaceutics names it directly as a pharmacokinetic–pharmacodynamic disconnect: a peptide with a sub-30-minute plasma half-life and modest intramuscular bioavailability is being credited with effects measured over days, without the pharmacodynamic profiling that would explain how.

There's no confirmed receptor. The mechanistic claims — growth hormone receptor upregulation, VEGFR2 signalling, nitric oxide pathway modulation — are downstream observations in animal tissue, not a mapped chain of cause and effect from an injection to a healed tendon. Until someone measures what BPC-157 does after it has left the bloodstream, dosing schedules of "twice daily for four weeks" are guesses dressed as protocols.

The development work that has never been done

The same 2026 Pharmaceutics review is worth reading in full because it inventories the absences rather than the promises. Its conclusions, in the authors' framing: no approved formulation, no validated dosing regimen, and no completed Phase II trial, despite more than three decades of preclinical work.

More specifically, it notes that no forced degradation studies under ICH Q1A stress conditions have been published for BPC-157. That is the standard, unglamorous stability testing every peptide drug substance goes through — heat, light, oxidation, pH — to establish shelf life and identify breakdown products. It hasn't been done in the open literature. Nor has anyone published work on the usual peptide formulation failure modes: aggregation, deamidation, adsorption to vial surfaces.

The practical consequence is blunt. Nobody can say, from published evidence, how much intact peptide is in a reconstituted vial after a fortnight in a fridge, because the study establishing that has never been published for this compound.

Myth check: does the "stable in gastric juice" claim mean oral works?

BPC-157 is frequently described as stable in human gastric juice, and that claim does trace to the original research. It's genuinely unusual for a peptide. But "survives the stomach" and "reaches the tissue you care about at a meaningful concentration" are different claims, and only the first has support.

There is no published human oral pharmacokinetic study of BPC-157. The oral absorption figures circulating online — 10–20%, 15–40%, take your pick — come from content sites, not from a paper measuring plasma concentrations in people after a capsule. Treat the range as marketing until a study exists. The animal work supporting oral dosing largely involves peptide dissolved in drinking water, in rodents, from the originating group.

Is BPC-157 legal in Australia? The regulatory position

This is the part with a clear answer.

Following an ACMS recommendation, the TGA created a Schedule 4 (Prescription Only) entry for BPC-157 and placed it in Appendix D, clause 5 — "poisons for which possession without authority is illegal" — effective 1 June 2024. Appendix D is the sharper edge: it isn't just that you need a script, it's that possessing the substance without appropriate authorisation is itself unlawful. The decision noted no registered products were affected, because there aren't any.

BPC-157 is approved as a medicine nowhere in the world. It has also been on the WADA Prohibited List since 2022, under S0 (non-approved substances) — prohibited at all times, in and out of competition. A short plasma half-life is not the same thing as a short detection window, and athletes should not assume otherwise.

In the United States, the compounding picture shifted through 2026: BPC-157 left the FDA's Category 2 bulk substances list in April after the nomination was withdrawn, and a July advisory committee vote followed — but an advisory vote is advisory. It remains not lawfully compoundable there. None of that changes the Australian schedule.

What would actually move this forward

A single well-run human pharmacokinetic study — plasma concentrations, metabolites, dose proportionality, in people — would do more for BPC-157's credibility than another twenty rodent papers. The published human record is currently a handful of uncontrolled pilot studies and case reports; the 2025 HSS Journal systematic review of BPC-157 in orthopaedic sports medicine found 35 of its 36 included studies were preclinical, with the single clinical entry a retrospective series in which 7 of 12 patients reported knee pain relief beyond six months. That is a starting point, not evidence of efficacy.

We track new BPC-157 research and TGA scheduling changes as they're published. Join the free updates list if you want them summarised without the sales pitch.

FAQ

How long does BPC-157 stay in your system?

In animal pharmacokinetic studies, the elimination half-life of intact BPC-157 was under 30 minutes — about 15 minutes in rats and roughly five minutes in dogs after intravenous dosing — with excretion via urine and bile. There is no published human pharmacokinetic study.

Is BPC-157 legal in Australia?

No, not without authorisation. Since 1 June 2024 BPC-157 has been Schedule 4 and listed in Appendix D of the Poisons Standard, which makes possession without appropriate authority illegal. It is not an approved medicine anywhere.

Are there human clinical trials of BPC-157?

Nothing substantial. The published human record consists of small uncontrolled pilot studies, case reports and retrospective series. A 2026 review in Pharmaceutics states there is no completed Phase II trial, no approved formulation and no validated dosing regimen.

Does oral BPC-157 actually work?

Unknown. BPC-157 is reported to be stable in gastric juice, but no human study has measured plasma levels after oral dosing, so the oral bioavailability percentages quoted online are not traceable to published human data.

Sources

This article is information only, not medical advice. BPC-157 is not an approved medicine in Australia or any other country and is Schedule 4 / Appendix D under the Poisons Standard. retatrutide.net.au is independent and not affiliated with any manufacturer, pharmacy or supplier.